Drug Trial Radar · NCT07083323
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
262
Planned (sponsor's estimate)
Start
Jul 22, 2025
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Sichuan Huiyu Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Peking University Cancer Hospital & Institute
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
HY05350 for injectionDrug
HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
HY05350 for injectionDrug
HY05350 should be administered intravenously at recommended dose, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, the occurrence of dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days).
- Part 1, Incidence of Treatment-Emergent Adverse Events (TEAE)Time frame: Up to 2 years.
- Part 2, Objective Response Rate (ORR)Time frame: Up to 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.